Literature DB >> 34676030

Imidazo[1,2-b]pyridazines as IL-17A Inhibitors for Treating Psoriasis, Rheumatoid Arthritis, and Multiple Sclerosis.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 34676030      PMCID： PMC8521613          DOI： 10.1021/acsmedchemlett.1c00470

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


× No keyword cloud information.
  5 in total

Review 1.  Newer Therapies in Psoriasis.

Authors:  Justin W Marson; Margaret L Snyder; Mark G Lebwohl
Journal:  Med Clin North Am       Date:  2021-07       Impact factor: 5.456

Review 2.  Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.

Authors:  Kamran Ghoreschi; Anna Balato; Charlotta Enerbäck; Robert Sabat
Journal:  Lancet       Date:  2021-01-27       Impact factor: 79.321

Review 3.  Pathogenesis of psoriatic arthritis.

Authors:  Carmel Stober
Journal:  Best Pract Res Clin Rheumatol       Date:  2021-06-06       Impact factor: 4.098

4.  Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis.

Authors:  Nikolai Loft; Anne-Sofie Halling; Alexander Egeberg; Lone Skov
Journal:  J Am Acad Dermatol       Date:  2020-07-28       Impact factor: 11.527

Review 5.  Psoriasis.

Authors:  Christopher E M Griffiths; April W Armstrong; Johann E Gudjonsson; Jonathan N W N Barker
Journal:  Lancet       Date:  2021-04-03       Impact factor: 79.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.